Sonia Servitja

67PUBLICATIONS
425CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersEconometric and statistical methodsMolecular targetsClinical midwifery
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (67)

|Jun 14, 2026
Abemaciclib in HR+, HER2- Breast Cancer: A Narrative Review of the Clinical Evidence.

|May 26, 2026
Sensitivity to endocrine therapy index predicts benefit from weekly adjuvant paclitaxel for hormone receptor-positive breast cancer in the GEICAM/9906 trial.

|May 26, 2026
Outcomes of Hormone receptor-positive/HER2-negative early breast cancer patients by risk of recurrence groups focusing on the intermediate-risk group: Retrospective analysis from GEICAM studies.

|Mar 13, 2026
ctDNA and tumor-based biomarkers of giredestrant response in acelERA breast cancer.

Ann E Collier, Stephanie Hilz, Alejandro M Chibly

|Mar 09, 2026
VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer.

Sara A Hurvitz, Rachel M Layman, Giuseppe Curigliano

|Dec 12, 2025
Neoadjuvant Abemaciclib plus Letrozole Versus Chemotherapy in Patients with HR+/HER2- Highly Proliferative Breast Cancer.

Miguel Martín, Ángel L Guerrero-Zotano, María E Pérez-López

Pageof 12

Frequent Collaborators

9 joint publications

José Angel García-Saenz

8 joint publications

Hope S Rugo

8 joint publications

Nadia Harbeck

7 joint publications

Erika P Hamilton